Donation supports testing efforts to help ensure continued access to essential services for children and their families
Novacyt S.A. (NCYT.L) Novacyt donates 1 million COVID-19 tests to UNICEF
Novacyt S.A. (NCYT.L) R&D and UK operational update
Paris, France and Camberley, UK – 23 April 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics.
Avacta Group PLC (AVCT.L) Final Results
Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
Novacyt S.A. (NCYT.L) Trading Update
Paris, France and Camberley, UK – 9 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its supply contract with
Stuart Quin, CEO of Medica Group Plc (MGP.L) Interview
Medica intends to lead the way in telemedicine and is the market leader in the UK and Ireland for the provision of teleradiology services, providing outsourced interpretation and reporting of
Avacta Group PLC (AVCT.L) Directorate Change
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down
Avacta Group PLC (AVCT.L) Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Vadim Alexandre, Healthcare Analyst, SP Angel talks diagnostic stocks.
The premise of this interview is to see what the landscape looks like with testing – diagnostic companies as we approach the vaccine salvation promised land, who will be the
Avacta Group PLC (AVCT.L) Significant momentum in both Diagnostics and Therapeutics Divisions
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
Avacta Group PLC (AVCT.L) Re: Press Speculation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, notes the recent press speculation about UK Government take-up of Avacta’s lateral flow SARS-CoV-2 rapid antigen test.
